SLCO1B1/SLC21A6 genotyping
Jump to navigation
Jump to search
Indications
- risk assessment for adverse drug effects of hepatically cleared drugs (SLCO1B1 gene variant affecting hepatic clearance)
- statin-induced myopathy (simvastatin)
- methotrexate therapy
More general terms
Additional terms
References
- ↑ Link E et al. SLCO1B1 variants and statin-induced myopathy. A genomewide study. N Engl J Med 2008 Aug 21; 359:789. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/18650507 <Internet> http://dx.doi.org/10.1056/NEJMoa0801936
- ↑ Ramsey LB, Johnson SG, Caudle KE et al The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014 Oct;96(4):423-8 PMID: https://www.ncbi.nlm.nih.gov/pubmed/24918167